Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. is positioned for revenue growth driven by strategic partnerships and an expanding oncology market, with anticipated margin improvements projected for 2026 and 2027 as operational efficiencies take effect. As the company transitions towards value-based care, incremental margin contributions are expected to enhance profitability, particularly through the growth of its dispensing and pharmacy services which leverage existing patient relationships. The removal of the DIR fee has further allowed for improved visibility on expenses, contributing to a rebound in margins by 2025, reinforcing the positive financial outlook for the company.

Bears say

The Oncology Institute Inc. is facing significant challenges that negatively impact its financial outlook, primarily due to contract losses in 2024 that adversely affected gross margins and anticipated continued pressure from new contract launches. The company's dispensary margins were notably impacted by the elimination of DIR fees, resulting in a $15 million headwind, while revenue growth in patient services remains subdued, likely trending flat or in low single digits compared to the industry growth rate of 11-14%. Additionally, the company is at risk of further financial strain from potential declines in coverage, increasing drug prices, and higher operational costs under risk-sharing arrangements, all of which could hinder its ability to achieve break-even EBITDA as projected.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.